Skip Viragh Center for Pancreatic Cancer Clinical Research and Patient Care
Our collaborative team of scientists, physicians and allied health workers specialize in translating science learned in the laboratory into exceptional clinical care. Our center is a world leader in the diagnosis and management of pancreatic cancer, leading all institutions in novel therapies, innovative clinical trials and in training the next generation of pancreatic cancer experts.
The Pancreatic Cancer Multidisciplinary Clinic, a one-day visit for new patients to meet with experts and have a comprehensive treatment plan decided by a panel of specialists, was first developed at Johns Hopkins in 2009. To date we have treated more than 2,100 patients. Many institutions around the world have come here to learn and adopt this model.
Request an Appointment
The Next Generation of Pancreatic Cancer Pioneers Skip Viragh Center fellows are helping advance the science and bringing much-needed new therapies to patients.
Pancreatic Cancer Matters Newsletter Immunology research for pancreatic cancer patients.
PancMD Video Series
An introduction to the Johns Hopkins experts who gather their knowledge and expertise for patients in the pancreatic cancer multidisciplinary clinic.
In understanding the science of cancer, investigators Bert Vogelstein, M.D., Kenneth Kinzler, Ph.D., and colleagues have deciphered the complete genetic blueprint for pancreatic cancer. Ralph Hruban, M.D., and Scott Kern, M.D., achieved the most advanced characterization of pancreatic cancer pathology.
In surgery, John Cameron, M.D., perfected the Whipple procedure, an operation to remove the head of the pancreas, most of the duodenum (a part of the small intestine), a portion of the bile duct, the gallbladder, and associated lymph nodes. Johns Hopkins surgeons now perform the most pancreatic cancer surgeries in the world.
In novel immunotherapies, Elizabeth Jaffee, M.D., developed the GVAX pancreatic cancer vaccine, now in clinical trials. Studies of what is likely to be the first immunotherapy for MSI-high tumors in pancreatic cancer approved by the FDA in 2017 was directed here.